This summary was created by AI, based on 3 opinions in the last 12 months.
Experts have a negative outlook on Organon (OGN-N) with a downward trend, poor fundamentals, and low growth. The stock has high debt levels and has not been able to beat earnings, making it a less attractive option for investors. The company seems to be stuck in the penalty box since its spinoff from Merck, even though it pays a high dividend at a low multiple of earnings. Overall, the consensus is that Organon is not a recommended buy due to its lack of growth and high debt levels.
Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.
Organon is a American stock, trading under the symbol OGN-N on the New York Stock Exchange (OGN). It is usually referred to as NYSE:OGN or OGN-N
In the last year, 1 stock analyst published opinions about OGN-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Organon.
Organon was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Organon.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Organon In the last year. It is a trending stock that is worth watching.
On 2024-10-11, Organon (OGN-N) stock closed at a price of $18.
Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.